Examples of using Ryzodeg in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
What is Ryzodeg?
Ryzodeg with alcohol.
How does Ryzodeg work?
Other information about Ryzodeg.
Ryzodeg causes a lower rate of overall and nocturnal hypoglycaemia Table 2.
Other medicines and Ryzodeg.
Ryzodeg has also been studied in one main study in 362 children aged between 1 and 17 years with type 1 diabetes.
Figure 1: Pharmacodynamics, single dose- Mean glucose infusion rate profile- Patients with type 1 diabetes-0.8 U/kg Ryzodeg- Trial 3539.
Ryzodeg 100 units/mL solution for injection in pre-filled pen Ryzodeg 100 units/mL solution for injection in cartridge.
It also noted that in the studies with adults Ryzodeg reduces the risk of hypoglycaemia during the night in patients with type 1 and type 2diabetes.
Ryzodeg plus OADs was compared to biphasic insulin aspart 30(BIAsp 30) b. i. d. plus OADs in two trials in type 2 diabetes mellitus Table 2.
As with other basal insulin products or insulin productswith a basal component, the prolonged effect of Ryzodeg may delay recovery from hypoglycaemia.
The CHMP concluded that Ryzodeg is effective in controlling blood glucose levels in adults, adolescents and children aged over 2 years with diabetes.
Because the dose requirements in young children may not be stable andbecause they cannot express symptoms of hypoglycaemia, Ryzodeg is not suitable for children aged under 2 years.
Ryzodeg comes in a cartridge(Penfill) designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist injection needles.
Skin changes where you use the injection(lipodystrophy): It is not known if Ryzodeg may cause lipodystrophy but such skin changes have been seen with other types of insulin.
Ryzodeg has been studied in one main study involving 548 adults with type 1 diabetes and in four main studies involving 1,866 adults with type 2 diabetes.
The steady-state pharmacokinetics properties of the insulin degludec component of Ryzodeg were investigated using population pharmacokinetic analysis in children down to 1 year of age.
Total exposure with Ryzodeg increases proportionally with increasing dose of the basal component(insulin degludec) and the meal-time component(insulin aspart) in type 1 and type 2 diabetes mellitus.
Patients switching from once-daily basal orpremix insulin therapy can be converted unit-to-unit to once-daily Ryzodeg at the same total insulin dose as the patient's previous total daily insulin dose.
Your doctor will decide with you: how much Ryzodeg you will need each day and at which meal(s) when to check your blood sugar level and if you need a higher or lower dose.
A lower rate of nocturnal hypoglycaemia(defined as episodes between midnight and 6 a.m. confirmed by plasma glucose< 3.1 mmol/l or by patient needing third party assistance)was observed with Ryzodeg relative to IGlar Table 1.
When changing from another insulin regimen to Ryzodeg, dose reduction of total insulin needs to be considered on an individual basis, in order to minimise the risk of hypoglycaemia see section 4.4.
Few severe hypoglycaemic episodes were reported in each group;the observed rate of severe hypoglycaemia within the Ryzodeg arm was higher for subjects aged 2-5 years compared to subjects aged 6-11 years or 12-17 years 0.42 vs 0.21 and 0.21 respectively.
The studies compared Ryzodeg given at mealtimes with insulin glargine or insulin detemir(long-acting insulins), or with biphasic insulin an insulin formulation consisting of a mixture of intermediate- and rapid-acting insulin.
There are no clinically relevant differences in the pharmacokinetics of Ryzodeg between elderly and younger adult patients, between races or between healthy subjects and patients with renal or hepatic impairment.
Ryzodeg dosed once daily with the main meal plus insulin aspart for the remaining meals showed similar reduction in HbA1c at week 16 and no differences in FPG and SMPG compared to comparator insulin detemir dosed once or twice daily plus mealtime insulin aspart.
The pharmacokinetic properties of Ryzodeg in type 1 diabetes mellitus were investigated in children(6-11 years) and adolescents(12-18 years) and compared to adults after single dose administration.
The pharmacodynamic effect of Ryzodeg is distinctively separated for the two components(Figure 1) and the resulting action profile reflects the individual components, the rapid-acting insulin aspart and the basal component insulin degludec.
The active substances in Ryzodeg, insulin degludec and insulin aspart, are produced by a method known as‘recombinant DNA technology': they are made by a yeast that has received a gene(DNA), which makes the yeast able to produce them.